Advanced Biomed Inc
ADVBHealthcare·Diagnostics & Research·Taiwan·Nano·NASD·Nov 10 • 3:59 PM ET
2.110.00 (0.00%)
2026-11-11 14:48 CET
Market cap
3.49 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-0.24 USD m
Free cash flow, TTM
-0.06 USD m
EPS diluted, TTM
-0.08
P/E
-
Price
ADVB against its 20, 50 and 200-day averages2050200
91.3% under 24.23 on 24 Jul 2026. Last 15 sessions, 122.2% high to low
Profile
ADVB52-week range, 1% of the way up
1.8024.23
Advanced Biomed, Inc. operates as a holding company with interests in developing biochip technologies. It engages in the research & development of microfluidic biochip technologies and provides tumor diagnosis and treatment technology applications. The company was founded by Yi Lu and Steven I-Fang Cheng in 2014 and is headquartered in Tainan, Taiwan.
| Employees | 12 |
|---|---|
| IPO | Mar 06, 2025 |
| Beta | 0.65 |
| ATR, 14d | 0.50 |
| Rel volume | 0.00 |
| Short float | 1.18% |
| Insider own | 42.70% |
| Inst own | 1.28% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | 3.49M |
| Enterprise Value | 3.51M |
| Income | -0.24M |
| Sales | 0.00M |
| Book/sh | 0.23 |
| Cash/sh | 0.01 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 12 |
| IPO | Mar 06, 2025 |
Ratios
| P/E | - |
|---|---|
| Forward P/E | - |
| PEG | - |
| P/S | - |
| P/B | 9.05 |
| P/C | 349.00 |
| P/FCF | - |
| EV/EBITDA | - |
| EV/Sales | - |
| Quick Ratio | 9.33 |
| Current Ratio | 9.33 |
| Debt/Eq | 0.08 |
| LT Debt/Eq | 0.00 |
| Option/Short | No / Yes |
Earnings
| EPS (ttm) | -0.08 |
|---|---|
| EPS next Y | - |
| EPS next Q | - |
| EPS this Y | - |
| EPS next Y | - |
| EPS next 5Y | - |
| EPS past 3/5Y | -18.91% -25.94% |
| Sales past 3/5Y | - - |
| EPS Y/Y TTM | 14.35% |
| Sales Y/Y TTM | - |
| EPS Q/Q | -1139.52% |
| Sales Q/Q | - |
| Earnings | - |
| EPS/Sales Surpr. | - - |
Ownership
| Insider Own | 42.70% |
|---|---|
| Insider Trans | 0.00% |
| Inst Own | 1.28% |
| Inst Trans | 43.40% |
| ROA | -60.71% |
| ROE | -78.78% |
| ROIC | -61.60% |
| Gross Margin | -110.23% |
| Oper. Margin | -5535.26% |
| Profit Margin | -5880.80% |
| SMA20 | -30.20% |
| SMA50 | -61.90% |
| SMA200 | -63.44% |
| Trades | - |
Technical
| Shs Outstand | 1.65M |
|---|---|
| Shs Float | 0.95M |
| Short Float | 1.18% |
| Short Ratio | 0.11 |
| Short Interest | 0.01M |
| 52W High | 24.23 -91.29% |
| 52W Low | 1.80 17.22% |
| Volatility | 17.56% 17.44% |
| ATR (14) | 0.50 |
| RSI (14) | 24.96 |
| Beta | 0.65 |
| Rel Volume | 0.00 |
| Avg Volume | 100.45K |
| Volume | 0 |
Performance
| Perf Week | -4.09% |
|---|---|
| Perf Month | -60.00% |
| Perf Quarter | -72.24% |
| Perf Half Y | -59.66% |
| Perf YTD | -63.85% |
| Perf Year | -74.12% |
| Perf 3Y | - |
| Perf 5Y | - |
| Perf 10Y | - |
| Recom | - |
| Target Price | - |
| Prev Close | 2.11 |
| Price | 2.11 |
| Change % | 0.00% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| BIAF | BioAffinity Technologies Inc | 4.55M |
| PRPO | Precipio Inc | 42.34M |
| MDXH | MDxHealth SA | 13.56M |
| BNR | Burning Rock Biotech Ltd ADR | 111.37M |
| IMDX | Insight Molecular Diagnostics Inc | 80.83M |
| QTRX | Quanterix Corp | 152.41M |
| XGN | Exagen Inc | 134.95M |
| BNGO | Bionano Genomics Inc | 16.49M |
| CODX | Co-Diagnostics Inc | 2.66M |
| LUCD | Lucid Diagnostics Inc | 85.59M |
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| No quarterly earnings. | |||||||
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| No annual earnings. | |||||
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| No estimate revisions. | ||||||||
Estimate history
| EPS, annual | -0.06 | -0.132 | -0.112 | -0.081 | -0.099 | -0.189 | |||
|---|---|---|---|---|---|---|---|---|---|
| Period | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |||
| EPS, quarterly | -0.004 | -0.008 | -0.026 | -0.039 | -0.021 | -0.012 | 0.204 | -0.012 | -0.26 |
| Period | Q2 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 |
| Sales, annual | 0 | 0 | 0 | 0 | 0 | 0.004 | |||
| Period | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |||
| Sales, quarterly | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.004 |
| Period | Q2 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 |
| Shares, annual | 1.082 | 1.082 | 1.082 | 1.082 | 1.082 | 1.652 | |||
| Period | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |||
| Shares, quarterly | 1.082 | 1.082 | 1.082 | 1.082 | 1.082 | 1.082 | 1.082 | 1.382 | 1.652 |
| Period | Q2 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 |
Income statement, annual
| Metric | TTM | 2026FY | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY |
|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | - | - | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
| Gross Profit | - | - | 0.00 | -0.01 | -0.01 | -0.00 | -0.00 |
| Selling, General and Administrative Excl. Other | 0.23 | 0.20 | 0.03 | 0.07 | 0.09 | 0.08 | 0.06 |
| Research and Development | - | - | 0.03 | 0.03 | 0.05 | 0.06 | 0.06 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -0.22 | -0.20 | -0.03 | -0.08 | -0.10 | -0.08 | -0.06 |
| Interest Expense | - | 0.00 | - | - | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.00 |
| Net Income Before Taxes | -0.20 | -0.20 | -0.03 | -0.09 | -0.12 | -0.14 | -0.06 |
| Income Taxes | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -0.20 | -0.20 | -0.03 | -0.09 | -0.12 | -0.14 | -0.06 |
| Net Income From Continuing Operations | -0.20 | -0.20 | -0.03 | -0.09 | -0.12 | -0.14 | -0.06 |
| Net Income | -0.24 | -0.24 | -0.10 | -0.09 | -0.12 | -0.14 | -0.06 |
| EPS (Recurring) | -0.14 | -0.19 | -0.10 | -0.08 | -0.11 | -0.09 | -0.06 |
| EPS (Basic, Before Extraordinaries) | -0.08 | -0.19 | -0.10 | -0.08 | -0.11 | -0.13 | -0.06 |
| EPS (Diluted) | -0.08 | -0.19 | -0.10 | -0.08 | -0.11 | -0.13 | -0.06 |
| EBITDA | -0.22 | -0.20 | -0.03 | -0.07 | -0.09 | -0.08 | -0.06 |
| Non-Operating Income (Expense) | 0.24 | -0.00 | 0.00 | -0.01 | -0.02 | -0.00 | -0.00 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | - | 0.04 | 0.00 | - | - | - | - |
| Price To Sales Ratio | 1,902.77 | 1,416.32 | - | - | - | - | - |
| Operating Margin | -5,535.26 | -4,883.59 | - | - | - | - | - |
| Net Margin | -5,880.80 | -5,749.13 | - | - | - | - | - |
| Shares Outstanding | 1.65 | 1.65 | 1.08 | 1.08 | 1.08 | 1.08 | 1.08 |
| Market Capitalization | 3.49 | 3.49 | 15.15 | 15.36 | - | - | - |
Income statement, quarterly
| Metric | 2026Q4 | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Selling, General and Administrative Excl. Other | 0.18 | 0.02 | 0.01 | 0.02 | 0.04 | 0.02 | 0.01 | 0.01 |
| Research and Development | - | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -0.18 | -0.02 | -0.01 | -0.02 | -0.04 | -0.02 | -0.02 | -0.02 |
| Interest Expense | 0.00 | 0.00 | - | - | - | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -0.40 | -0.02 | 0.23 | -0.01 | -0.02 | -0.04 | -0.03 | -0.01 |
| Income Taxes | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -0.40 | -0.02 | 0.23 | -0.01 | -0.02 | -0.04 | -0.03 | -0.01 |
| Net Income From Continuing Operations | -0.40 | -0.02 | 0.23 | -0.01 | -0.02 | -0.04 | -0.03 | -0.01 |
| Net Income | -0.43 | -0.02 | 0.22 | -0.01 | -0.02 | -0.04 | -0.03 | -0.01 |
| EPS (Recurring) | -0.26 | -0.01 | 0.20 | -0.01 | -0.02 | -0.04 | -0.03 | -0.01 |
| EPS (Basic, Before Extraordinaries) | -0.26 | -0.01 | 0.20 | -0.01 | -0.02 | -0.04 | -0.03 | -0.01 |
| EPS (Diluted) | -0.26 | -0.01 | 0.20 | -0.01 | -0.02 | -0.04 | -0.03 | -0.01 |
| EBITDA | -0.18 | -0.02 | -0.01 | -0.02 | -0.04 | -0.02 | -0.01 | -0.01 |
| Non-Operating Income (Expense) | -0.00 | 0.00 | 0.24 | 0.00 | 0.02 | -0.02 | -0.01 | 0.01 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.04 | - | - | - | - | - | - | - |
| Price To Earnings Ratio | - | 34.44 | 44.08 | - | - | - | - | - |
| Price To Sales Ratio | 1,902.77 | - | - | - | - | - | - | - |
| Operating Margin | -4,377.96 | - | - | - | - | - | - | - |
| Net Margin | -10,650.73 | - | - | - | - | - | - | - |
| Shares Outstanding | 1.65 | 1.38 | 1.08 | 1.08 | 1.08 | 1.08 | 1.08 | 1.08 |
| Market Capitalization | 3.49 | 6.22 | 6.31 | 9.70 | 15.15 | 84.83 | 86.56 | - |
Balance sheet, annual
| Metric | 2026FY | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 0.01 | 0.00 | 0.08 | 0.08 | 0.16 | 0.00 |
| Short Term Receivables | 0.42 | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.77 | 0.01 | 0.00 | 0.00 | 0.03 |
| Total Current Assets | 0.43 | 0.77 | 0.09 | 0.09 | 0.17 | 0.03 |
| Net Property, Plant & Equipment | 0.00 | 0.00 | 0.02 | 0.03 | 0.04 | 0.00 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Deferred Tax Assets | 0.00 | 0.00 | - | - | - | - |
| Other Assets | 0.00 | 0.02 | 0.02 | 0.02 | 0.00 | 0.00 |
| Total Assets | 0.43 | 0.78 | 0.14 | 0.15 | 0.23 | 0.04 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.03 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 |
| Accounts Payable | 0.00 | 0.00 | 0.02 | 0.02 | 0.03 | 0.00 |
| Other Current Liabilities | 0.01 | 0.66 | 0.06 | 0.08 | 0.07 | 0.00 |
| Total Current Liabilities | 0.05 | 0.66 | 0.08 | 0.11 | 0.10 | 0.00 |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 0.05 | 0.66 | 0.09 | 0.11 | 0.11 | 0.00 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 0.39 | 0.12 | 0.05 | 0.04 | 0.12 | 0.04 |
| Total Shareholders Equity | 0.39 | 0.12 | 0.05 | 0.04 | 0.12 | 0.04 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 0.39 | 0.12 | 0.05 | 0.04 | 0.12 | 0.04 |
| Total Liabilities & Stockholders Equity | 0.43 | 0.78 | 0.14 | 0.15 | 0.23 | 0.04 |
| Book Value Per Share | 0.23 | 0.11 | 0.05 | 0.04 | 0.11 | 0.03 |
| Tangible Book Value Per Share | 0.23 | 0.11 | 0.04 | 0.03 | 0.10 | 0.03 |
| Full-Time Employees | 12 | 31 | 40 | 40 | - | - |
| Price to Book Ratio | 9.05 | 127.25 | 123.52 | - | - | - |
| Return on Assets | -61.64 | -7.36 | -61.30 | -65.07 | -108.76 | - |
| Return on Equity | -79.99 | -39.75 | -187.60 | -152.52 | -186.83 | - |
| Return on Invested Capital | -61.36 | -83.60 | -164.13 | -285.77 | -113.73 | -183.80 |
| Quick Ratio | 9.33 | 1.16 | 1.12 | 0.85 | 1.67 | 32.22 |
| Current Ratio | 9.33 | 1.16 | 1.12 | 0.85 | 1.67 | 32.22 |
Cash flow, annual
| Metric | TTM | 2026FY | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY |
|---|---|---|---|---|---|---|---|
| Net Income | 0.21 | 0.22 | -0.10 | -0.09 | -0.12 | -0.14 | -0.06 |
| Depreciation | - | - | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Other Funds (Non Cash) | -0.28 | -0.28 | -0.04 | 0.00 | 0.00 | 0.06 | 0.00 |
| Funds from Operations | -0.07 | -0.07 | -0.14 | -0.07 | -0.10 | -0.08 | -0.06 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 0.00 | 0.00 | -0.04 | 0.01 | 0.01 | 0.05 | 0.05 |
| Cash from Operating Activities | -0.06 | -0.06 | -0.18 | -0.07 | -0.10 | -0.03 | -0.02 |
| Capital Expenditures | -0.00 | 0.00 | 0.00 | -0.00 | -0.01 | -0.05 | -0.00 |
| Net Assets From Acquisitions | -0.08 | -0.08 | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Cash from Investing Activities | -0.08 | -0.08 | -0.00 | -0.00 | -0.01 | -0.04 | -0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.01 | 0.01 | 0.17 | -0.00 | 0.01 | 0.22 | 0.02 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.01 | 0.01 | 0.17 | -0.00 | 0.01 | 0.22 | 0.02 |
| Proceedsfrom Stock Options | 0.01 | 0.01 | 0.17 | -0.00 | 0.01 | 0.22 | 0.02 |
| Issuance or Reduction of Debt, Net | 0.03 | 0.03 | 0.01 | 0.05 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.03 | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.03 | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.02 | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 0.06 | 0.06 | 0.18 | 0.06 | 0.01 | 0.22 | 0.02 |
| Exchange Rate Effect | -0.00 | -0.00 | 0.01 | 0.01 | 0.02 | 0.02 | -0.01 |
| Net Change in Cash | -0.08 | -0.08 | 0.01 | -0.00 | -0.07 | 0.17 | 0.00 |
| Free Cash Flow | -0.06 | -0.06 | -0.18 | -0.07 | -0.10 | -0.06 | -0.02 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q4 | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 0.01 | 0.08 | 0.08 | 0.09 | 0.10 | 0.16 |
| Short Term Receivables | 0.42 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.24 | 0.26 | 0.09 | 0.10 | 0.07 |
| Total Current Assets | 0.43 | 0.33 | 0.34 | 0.19 | 0.21 | 0.23 |
| Net Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | - | - | - | 0.00 | 0.00 |
| Deferred Tax Assets | 0.00 | - | - | - | - | - |
| Other Assets | 0.00 | 7E-05 | 3E-05 | 0.00 | 0.00 | 0.00 |
| Total Assets | 0.43 | 0.33 | 0.35 | 0.20 | 0.22 | 0.25 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.03 | 0.02 | 0.02 | 0.05 | 0.04 | 0.00 |
| Accounts Payable | 0.00 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 |
| Income Tax Payable | - | 0.00 | 0.00 | - | - | - |
| Other Current Liabilities | 0.01 | 0.01 | 0.01 | 0.03 | 0.04 | 0.10 |
| Total Current Liabilities | 0.05 | 0.04 | 0.04 | 0.10 | 0.10 | 0.12 |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 0.05 | 0.04 | 0.04 | 0.11 | 0.10 | 0.13 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 0.39 | 0.29 | 0.30 | 0.10 | 0.12 | 0.12 |
| Total Shareholders Equity | 0.39 | 0.29 | 0.30 | 0.10 | 0.12 | 0.12 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 0.39 | 0.29 | 0.30 | 0.10 | 0.12 | 0.12 |
| Total Liabilities & Stockholders Equity | 0.43 | 0.33 | 0.35 | 0.20 | 0.22 | 0.25 |
| Book Value Per Share | 0.23 | 0.21 | 0.28 | 0.09 | 0.11 | 0.11 |
| Tangible Book Value Per Share | 0.23 | 0.21 | 0.28 | 0.09 | 0.11 | 0.11 |
| Full-Time Employees | 12 | - | - | - | 31 | - |
| Price to Book Ratio | 9.05 | 16.35 | 20.93 | 98.38 | 127.25 | 681.98 |
| Return on Assets | -60.71 | 59.90 | 61.27 | -61.12 | - | - |
| Return on Equity | -78.78 | 84.61 | 92.23 | -158.93 | - | - |
| Return on Invested Capital | -111.57 | -5.36 | 72.34 | -12.32 | -18.31 | -33.47 |
| Quick Ratio | 9.33 | 7.38 | 8.56 | 1.92 | 2.09 | 1.88 |
| Current Ratio | 9.33 | 7.38 | 8.56 | 1.92 | 2.09 | 1.88 |
Cash flow, quarterly
| Metric | 2026Q4 | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 |
|---|---|---|---|---|---|---|
| Net Income | 0.01 | -0.02 | 0.23 | -0.01 | -0.03 | -0.04 |
| Depreciation | - | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 |
| Other Funds (Non Cash) | -0.02 | 0.01 | -0.27 | 0.00 | 0.00 | 0.00 |
| Funds from Operations | -0.01 | -0.01 | -0.04 | -0.01 | -0.02 | -0.04 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -0.01 | 0.01 | 0.02 | -0.01 | -0.03 | -0.06 |
| Cash from Operating Activities | -0.02 | -0.01 | -0.02 | -0.02 | -0.06 | -0.10 |
| Capital Expenditures | 0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Net Assets From Acquisitions | -0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -0.08 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | 0.17 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | 0.17 |
| Proceedsfrom Stock Options | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 | 0.17 |
| Issuance or Reduction of Debt, Net | 0.03 | 0.00 | -0.01 | 0.01 | 0.01 | 0.00 |
| Change in Long Term Debt | 0.03 | 0.00 | -0.01 | 0.02 | 0.01 | 0.00 |
| Issuance of Long Term Debt | 0.03 | -0.00 | -0.01 | 0.02 | 0.03 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | -0.00 | 0.00 | -0.02 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | -0.00 | 0.02 | 0.00 | -0.03 | 0.01 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 0.03 | 0.01 | 0.01 | 0.01 | -0.01 | 0.18 |
| Exchange Rate Effect | -0.00 | -0.00 | 0.01 | -0.00 | 0.00 | 0.00 |
| Net Change in Cash | -0.07 | 0.00 | -0.00 | -0.01 | -0.07 | 0.08 |
| Free Cash Flow | -0.02 | -0.01 | -0.02 | -0.02 | -0.06 | -0.10 |
Revenue breakdown
| Services-Medical Laboratories | 2026: 127.64K |
|---|---|
| United States | 2026: 127.64K |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 1.18% | 0.0M | 1.0M | 117.96K |
| 2026-10-15 | 1.03% | 0.0M | 1.0M | 1.72M |
| 2026-09-30 | 2.55% | 0.0M | 0.7M | 1.75M |
| 2026-09-15 | 1.33% | 0.0M | 0.7M | 1.77M |
| 2026-08-31 | 2.21% | 0.0M | 0.7M | 1.73M |
| 2026-08-14 | 5.05% | 0.0M | 0.7M | 1.72M |
| 2026-07-31 | 10.22% | 0.1M | 0.6M | 1.78M |
| 2026-07-15 | 1.89% | 0.0M | 0.6M | 124.84K |
| 2026-06-30 | 4.40% | 0.0M | 0.4M | 428.41K |
| 2026-06-15 | 1.25% | 0.0M | 0.7M | 448.29K |
| 2026-05-29 | 0.34% | 0.0M | 0.6M | 555.99K |
| 2026-05-15 | 0.64% | 0.0M | 0.6M | 576.64K |
| 2026-04-30 | 2.31% | 0.0M | 0.6M | 487.42K |
| 2026-04-15 | 13.29% | 0.0M | 0.4M | 487.59K |
| 2026-03-31 | 7.08% | 0.0M | 0.4M | 169.85K |
| 2026-03-13 | 3.47% | 0.0M | 0.4M | 140.31K |
| 2026-02-27 | 6.14% | 0.0M | 0.4M | 52.12K |
| 2026-02-13 | 0.34% | 0.0M | 1.1M | 26.66K |
| 2026-01-30 | 1.51% | 0.0M | 0.3M | 29.98K |
| 2026-01-15 | 4.97% | 0.0M | 0.2M | 61.73K |
Option chain
expiry 2026-11-11| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-10-13 | 10-K | Annual report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-09-28 | NT 10-K | 2026-06-30 | SEC | |
| 2026-09-22 | SCHEDULE 13G | SEC | ||
| 2026-08-20 | SCHEDULE 13G/A | SEC | ||
| 2026-08-20 | SCHEDULE 13G | SEC | ||
| 2026-07-20 | RW | Registration Withdrawal Request | SEC | |
| 2026-07-17 | 8-K | Current report | 2026-07-14 | SEC |
| 2026-07-01 | 8-K | Current report | 2026-06-30 | SEC |
| 2026-06-30 | 8-K | Current report | 2026-06-30 | SEC |
| 2026-06-04 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-06-30 | SEC |
| 2026-05-15 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-05-01 | 8-K | Current report | 2026-04-28 | SEC |
| 2026-04-14 | 8-K | Current report | 2026-04-13 | SEC |
| 2026-04-03 | 8-K | Current report | 2026-04-02 | SEC |
| 2026-03-30 | 8-K | Current report | 2026-03-25 | SEC |
| 2026-03-16 | 8-K | Current report | 2026-03-12 | SEC |
| 2026-02-26 | 8-K | Current report | 2026-02-20 | SEC |
| 2026-02-13 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2025-12-31 | SEC |
| 2026-02-10 | 8-K/A | 2025-06-06 | SEC | |
| 2026-02-02 | 8-K | Current report | 2026-01-28 | SEC |
| 2026-01-27 | 8-K | Current report | 2026-01-26 | SEC |
| 2026-01-23 | DEF 14C | Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 | 2026-01-23 | SEC |
| 2026-01-21 | 8-K | Current report | 2026-01-16 | SEC |
| 2026-01-12 | PRE 14C | Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 | 2026-01-12 | SEC |
| 2025-12-30 | 8-K | Current report | 2025-12-23 | SEC |
| 2025-11-19 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2025-09-30 | SEC |
| 2025-11-14 | NT 10-Q | 2025-09-30 | SEC | |
| 2025-10-08 | 10-K | Annual report pursuant to Section 13 or 15(d) | 2025-06-30 | SEC |
| 2025-09-30 | NT 10-K | 2025-06-30 | SEC | |
| 2025-09-19 | 8-K | Current report | 2025-09-19 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 1.22% |
| UBS Group AG | 0.27% |
| VALLEY NATIONAL ADVISERS INC | 0.06% |
| Caitong International Asset Management Co., Ltd | 0.00% |
Funds
| Fund | % owned |
|---|---|
| Fidelity Nasdaq Composite Index Fund | 1.34% |
OakChart. ADVB. Cached 15 minutes.
Some panels did not load: ratings, insider, news.